Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Ann Rheum Dis ; 65(10): 1325-9, 2006 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16540546

RESUMEN

OBJECTIVE: To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc). PARTICIPANTS AND METHODS: 134 people participated in a 2-year, double-blind, randomised clinical trial comparing efficacy of low-dose and high-dose D-penicillamine in diffuse SSc. At 6, 12, 18 and 24 months, the investigator was asked to rate the change in the patient's health since entering the study: markedly worsened, moderately worsened, slightly worsened, unchanged, slightly improved, moderately improved or markedly improved. Patients who were rated as slightly improved were defined as the minimally changed subgroup and compared with patients rated as moderately or markedly improved. RESULTS: The MID estimates for the mRSS improvement ranged from 3.2 to 5.3 (0.40-0.66 effect size) and for the HAQ-DI from 0.10 to 0.14 (0.15-0.21 effect size). Patients who were rated to improve more than slightly were found to improve by 6.9-14.2 (0.86-1.77 effect size) on the mRSS and 0.21-0.55 (0.32-0.83 effect size) on the HAQ-DI score. CONCLUSION: MID estimates are provided for improvement in the mRSS and HAQ-DI scores, which can help in interpreting clinical trials on patients with SSc and be used for sample size calculation for future clinical trials on diffuse SSc.


Asunto(s)
Antirreumáticos/administración & dosificación , Indicadores de Salud , Penicilamina/administración & dosificación , Esclerodermia Difusa/tratamiento farmacológico , Adulto , Antirreumáticos/uso terapéutico , Evaluación de la Discapacidad , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Penicilamina/uso terapéutico , Esclerodermia Difusa/rehabilitación , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
2.
Rheum Dis Clin North Am ; 26(1): 75-81, viii-ix, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10680195

RESUMEN

Although several case reports and case series suggest efficacy for photopheresis in the treatment of autoimmune diseases, few controlled studies have been conducted to test this hypothesis. After a decade of interest, multiple case reports, open trials, and one controlled study, the role of photopheresis in autoimmune disease remains to be established. Controlled multi-center trials in rheumatoid arthritis, SLE, and scleroderma may be costly but are clearly necessary for proper evaluation of this therapy.


Asunto(s)
Enfermedades Autoinmunes/terapia , Fotoféresis , Terapias Complementarias , Humanos
3.
Am J Epidemiol ; 149(8): 761-70, 1999 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-10206626

RESUMEN

Occupational solvent exposure may increase the risk of connective tissue disease (CTD). The objective of this case-control study was to investigate the relation between undifferentiated connective tissue disease (UCTD) and solvent exposure in Michigan and Ohio. Women were considered to have UCTD if they did not meet the American College of Rheumatology classification criteria for any CTD but had at least two documented signs, symptoms, or laboratory abnormalities suggestive of a CTD. Detailed information on solvent exposure was ascertained from 205 cases, diagnosed between 1980 and 1992, and 2,095 population-based controls. Age-adjusted odds ratios (OR) and 95 percent confidence intervals (CI) were calculated for all exposures. Among 16 self-reported occupational activities with potential solvent exposure, furniture refinishing (OR = 9.73, 95 percent CI 1.48-63.90), perfume, cosmetic, or drug manufacturing (OR = 7.71, 95 percent CI 2.24-26.56), rubber product manufacturing (OR = 4.70, 95 percent CI 1.75-12.61), work in a medical diagnostic or pathology laboratory (OR = 4.52, 95 percent CI 2.27-8.97), and painting or paint manufacturing (OR = 2.87, 95 percent CI 1.06-7.76) were significantly associated with UCTD. After expert review of self-reported exposure to ten specific solvents, paint thinners or removers (OR = 2.73, 95 percent CI 1.80-4.16) and mineral spirits (OR = 1.81, 95 percent CI 1.09-3.02) were associated with UCTD. These results suggest that exposure to petroleum distillates increases the risk of developing UCTD.


Asunto(s)
Contaminantes Ocupacionales del Aire/efectos adversos , Enfermedades del Tejido Conjuntivo/inducido químicamente , Enfermedades Profesionales/inducido químicamente , Petróleo/efectos adversos , Solventes/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades del Tejido Conjuntivo/epidemiología , Femenino , Humanos , Michigan , Persona de Mediana Edad , Enfermedades Profesionales/epidemiología , Ohio , Factores de Riesgo
4.
Arch Dermatol ; 125(1): 70-6, 1989 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2910208

RESUMEN

Histologic paraffin sections of pseudoxanthoma elasticum (PXE)-involved skin of forearm and axilla were used for histochemistry and immunohistochemical and analytical electron microscopy to study the progressive mineralization in the dermis of patients with PXE. The von Kossa technique identified mineral deposits throughout the reticular PXE dermis. X-ray analysis revealed patterns of calcium and phosphorus deposition in the von Kossa-positive areas, and the immunohistochemical staining using monoclonal antibodies identified increased chondroitin-6-sulfate in these areas when compared with normal skin. Scanning transmission electron microscopy observation combined with X-ray dot mapping show calcium and phosphorus to be codistributed within the mineralized area. This study confirms by new methods the increase in chondroitin-6-sulfate, alterations in elastin and collagen, and a high calcium and phosphorus elemental distribution matching the mineralized area in the PXE dermis.


Asunto(s)
Proteínas de la Matriz Extracelular , Minerales/metabolismo , Seudoxantoma Elástico/patología , Piel/patología , Calcio/metabolismo , Colágeno/metabolismo , Proteínas Contráctiles/metabolismo , Tejido Elástico/metabolismo , Tejido Elástico/patología , Elastina/metabolismo , Microanálisis por Sonda Electrónica , Matriz Extracelular/patología , Humanos , Inmunohistoquímica , Microscopía Electrónica , Fósforo/metabolismo , Proteoglicanos/metabolismo , Seudoxantoma Elástico/metabolismo , Factores de Empalme de ARN , Piel/metabolismo , Piel/ultraestructura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA